Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?
GROUND AND OBJECTIVE: Attention deficit hyperactivity disorder (ADHD) is the most common psychiatric disorder in children and adolescents (6-12% affected). Treatment with methylphenidate (MPH) in the United States has increased to a current prescription rate of > 5 million per year. However, a 2005 study by El-Zein and co-workers [Cancer Lett 230:284-291] reporting a 3-fold increase in genomic damage in all 12 analyzed children after 3 months of therapy with MPH resulted in much concern about potential carcinogenic effects. Here we provide new information concerning the cytogenetic effect of MPH in children. DESIGN, PARTICIPANTS, AND METHODS: In a prospective study, we analyzed the genomic damage in children with ADHD (initial sample size 38 children) before and 1 (30 children), 3 (21 children), and 6 (8 children) months after initiation of MPH therapy. In addition, we investigated a group of 9 children receiving chronic MPH therapy. Patients were recruited within a study of our Clinic
Related Questions
- Does atomoxetine increase the risk of aggression and hostility in children with attention deficit hyperactivity disorder (ADHD)?
- Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder?
- Should Children Receive Medication for Symptoms of Attention Deficit Hyperactivity Disorder?